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At our institution, most patients eligible
for LVR undergo a preoperative EP study.
In patients with spontaneous or inducible
ventricular tachycardia (VT), we perform
endocardial resection and cryoablation. In
patients with preoperative clinical VT, we
perform an EP study before hospital dis-
charge, and in patients with inducible-only
VT, we perform an EP study 3 to 6 months
after the operation. In case of postoperative
clinical or inducible VT, we recommend
ICD implantation. We have recently re-
ported our experience in a series of 53
consecutive patients undergoing LVR and
surgical intervention for VT.3 The success
rate in terms of VT control was 90%. This
finding is comparable to the results previ-
ously reported by Di Donato and col-
leagues4 and Mickleborough and associ-
ates.5
Treat the cause, not the symptoms.
ICD firing is associated with a certain
amount of discomfort for the patient.
ICDs indisputably save lives, but the
price can be high both in terms of money
and patient well-being. Therefore the aim
must be to eliminate the need for ICD. By
adding specific antiarrhythmic surgical
procedures, such as endocardectomy and
cryoablation, in patients undergoing
LVR, we have a potentially curative
treatment option at our disposal. In our
view an EP study is necessary after LVR
when surgical intervention for VT has
been included to identify surgical failures
in which ICD therapy is warranted.
In our opinion patients scheduled for
LVR should be assessed for ventricular
arrhythmias, and if present, specific ar-
rhythmia surgery should be performed
con-
comitantly, and the postoperative result
should be verified by means of EP stud-
ies. With this protocol, implantation of an
ICD will not be needed in most patients
after LVR including surgical intervention
for VT.
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Reply to the Editor:
As stated in the article, 30 patients had im-
plantable cardiovertor-defibrillators inserted
preoperatively, and the indication for the ma-
jority of these patients was secondary preven-
tion, having had either a documented ventric-
ular arrhythmia or aborted sudden death. Of
these 30 patients, 2 had aborted sudden
cardiac death, 3 had sustained ventricular
tachycardia, and the remainder presumably
had positive electrophysiologic (EP) stud-
ies. For groups 2 and 3 of our series, we do
not have accurate data on who underwent
EP studies preoperatively.
Dr Sartipy’s group performs EP studies
preoperatively. This approach is used to guide
endocardial resection or cryoablation. Many
of our patients (13%) underwent cryoablation
for arrhythmias. However, the main indica-
tion for left ventricular reconstruction (LVR)
was heart failure, rather than intractable ar-
rhythmias.
LVR definitely has a role in the treat-
ment of ventricular arrhythmias, but in pa-
tients with severe left ventricular dysfunc-
tion, border zones between scar and viable
myocardium might provide arrhythmic sub-
strate. In addition, patients in our series had
evidence of marked left ventricular remod-
elling, with arrhythmic substrate in areas
remote to the site of LVR.
Against that, the Coronary Artery Bypass
Graft Patch Trial1 failed to show a reduction
in mortality when patients with markers for
increased risk of ventricular arrhythmia un-
derwent implantable cardioverter-defibrillator
implantation at the time of coronary artery
bypass grafting. This has been attributed to
a reduction in the risk of arrhythmic death as
a result of revascularization.2 This indicates
that perhaps the most important procedure to
reduce arrhythmias is surgical revasculariza-
tion.
Further prospective studies are required
to elucidate the optimal strategy in this com-
plex group of patients.
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Left ventricular assist device in
heart failure
To the Editor:
I read with great interest the article by
Nicholas C. Dang and colleagues, wherein
they report their experience with left ven-
tricular assist device (LVAD) in patients
with chronic congestive heart failure.1 There
are various mechanical circulatory devices
employed currently as a bridge to trans-
plantation. The authors report their experi-
ence with the HeartMate (Thoratec Corp,
Pleasanton, CA) device; however, the type
of device engaged is not mentioned. It is
pertinent to note that of HeartMate LVADs,
the single-lead vented electrical devices have
been linked with the best posttransplant
survival rates.2
Even as vigilance for the predictive
factors1 will help in patient selection, im-
proved clinical outcome should also be
sought by careful timing of transplantation
following LVAD insertion. By instituting
patient support and rehabilitation for at
least a month following the implantation,
significant normalization of end-organ func-
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tion and improvement in physiologic status
may be achieved to improve survival follow-
ing the transplant.3
A possible scoring system for better se-
lection of patient criteria is sought. In this
context the Acute Physiology and Chronic
Health Evaluation II (APACHE II) scoring
system, a multiparameter, physiology-based
predictor of outcome, might be helpful. It can
aid in both selection and timing of LVAD
implantation, particularly in patients not
meeting normal hemodynamic criteria for
LVAD usage.4
Development of right ventricular failure
often causes poor results in patients with
LVADs. It is important to take into consid-
eration the predictive factors including the
need for circulatory support, female gender,
and nonischemic etiology, along with the he-
modynamic alterations including low pulmo-
nary artery pressure and low right ventricle
stroke work index, that might indicate poor
right ventricular outcome.5 Careful observa-
tion of the above would assist both in pa-
tient selection and clinical handling of
isolated LVAD implants.
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Reply to the Editor:
We thank Dr Ashraf for his comments on
our recent article concerning the use of left
ventricular assist devices (LVADs) in pa-
tients with chronic congestive heart fail-
ure.1 His letter invites us to discuss several
important points.
First, to clarify the device type used pre-
dominantly at our center and used exclu-
sively in our study, we favor the HeartMate
XVE (single-lead vented electric) LVAD
(Thoratec Corp, Pleasanton, CA) for its rela-
tive ease of implantation, durability, and lack
of need for systemic anticoagulation. Our
long-term experience with this device has
paralleled an evolution in design, resulting in
improved bridge-to-transplant and posttrans-
plant survival rates.2
Next, we could not agree more with Dr
Ashraf’s observation that the timing of
transplantation following LVAD insertion
plays a critical role in determining survival.
Our own unpublished data show near nor-
malization of blood urea nitrogen, creatinine,
and liver function values at approximately 3
months of support time, bolstering the con-
cept of enhanced end-organ perfusion by the
LVAD. Moreover, the smooth transition to
cardiac rehabilitation and nutritional optimi-
zation throughout the recovery period are of
critical importance.
Although we do not employ the Acute
Physiology and Chronic Health Evaluation
II (APACHE II) scoring system ourselves,
we use similar clinical and laboratory-
based parameters to select LVAD candi-
dates. All patients referred for LVAD are
generally refractory to maximal medical ther-
apy, which often includes the use of intrave-
nous inotropes, vasopressors, and intra-aortic
balloon pumps. Exclusion is therefore done
on the basis of such factors as ventilatory
status, elevated pulmonary pressures, and pro-
longed prothrombin time.
Despite the physiologic benefits of LVADs,
even as they apply to the right ventricle,
right heart failure (RHF) occurs in approx-
imately 15% to 20% of patients postoper-
atively.3,4 Multiple studies have sought to
identify demographic and hemodynamic risk
factors predictive of the development of
RHF, but in practice, these parameters often
exhibit variable outcomes. Although the best
treatment for RHF is avoidance, when it does
become manifest, a low threshold should be
maintained to promptly start inotropic (ie,
milrinone) and pulmonary vasodilator (ie, ni-
tric oxide) therapy, with a right ventricular
assist device close at hand.
Nicholas C. Dang, MD
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Apoptosis in ischemic spinal cord
injury
To the Editor:
We read the article of Suzuki and associ-
ates1 titled “Experimental study on the pro-
tective effects of edaravone against isch-
emic spinal cord injury” with great interest.
They studied the effect of a free radical scav-
enger named “edaravone” in a rabbit model
of transient aortic occlusion and claimed its
protective effect on the ischemia-reperfusion
injury of spinal cord by suppressing the level
of reactive oxygen species (ROS). We con-
gratulate Suzuki and associates for their ex-
cellent study. We think that the introduction
of microdialysis method to determine the
production of ROS in the neuronal tissue
after transient ischemia for the first time in
the literature by the authors is a great con-
tribution to our current knowledge.
Recently, data has accumulated that
programmed cell death or apoptosis of mo-
tor neurons in spinal cord after transient
ischemia is an outstanding mechanism of
postoperative paraplegia or paraparesis.2,3
The neuronal injury following transient aortic
occlusion occurs in 2 phases, namely, early
and delayed. Ischemic insult in spinal cord
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